Skip to main content

Table 1 Main clinical features of enrolled RA patients

From: Reduced T-cell repertoire restrictions in abatacept-treated rheumatoid arthritis patients

 

Total cohort of patients (n = 44)

RA patients evaluated for TCRBV a repertoire and TERT b (n = 17)

p

Sex (male/female)

6/38

4/13

0.300

Age, years (range)

54 (47-60)

57 (48-60)

0.412

Rheumatoid factor positivity

33 (75%)

12 (70%)

0.979

AntiCCPc positivity

36 (82%)

15 (88%)

0.825

Disease duration, years (range)

8 (4-13)

4 (2-7)

0.001

Smokers

14 (32%)

7 (41%)

0.697

Comorbidities:

   

Arterial hypertension

17

4

0.416

Diabetes mellitus

4

1

0.223

Cardio-vascular events

4

0

0.478

Number of previous DMARDsd

3 (2-5)

2 (2-3)

0.001

Previous biological agents:

   

Infliximab

21

5

0.313

Etanercept

27

8

0.256

Adalimumab

28

9

0.635

Rituximab

9

1

0.321

Tocilizumab

4

3

0.623

Anakinra

6

2

0.999

DAS28-CRP at baseline (range)

5.10 (4.40-5.97)

5.06 (4.41-5.46)

0.185

Median dosage of methotrexate at baseline (range)

12.5 (6.25-15)

15 (10-15)

0.042

Median number of DMARDs at baseline (range)

1 (1-1)

1 (1-1)

0.022

  1. aTCRBV: T-cell receptor variable beta; b TERT: telomerase reverse transcriptase; cAnti-CCP: anti-cyclic citrullinated peptide antibodies; dDMARDs: disease modifying anti-rheumatic drugs.